Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Ann Surg Oncol. 2021 Oct;28(11):6366-6375. doi: 10.1245/s10434-021-09875-2. Epub 2021 Mar 25.
We compare planned salvage surgery after definitive chemoradiotherapy (SALV) versus neoadjuvant chemoradiotherapy plus surgery (NCRS) for borderline resectable T4 esophageal squamous cell carcinoma.
A total of 37 patients underwent planned SALV, and 20 underwent NCRS from 2004 to 2017. The short-term outcome measures were the R0 resection rate, complications, and treatment-related mortality. The long-term outcome measures were the 5-year overall survival rate and causes of death.
R0 resection rate was similar between the SALV and NCRS groups (81% versus 85%). The incidence of postoperative pneumonia (35% versus 18%) and treatment-related mortality rate (9% versus 0%) tended to be higher in the SALV. ypT grade 2-3 (65% versus 30%, p = 0.012) and Clavien-Dindo grade ≥ IIIb complications (32% versus 0%, p = 0.008) were significantly more frequent in the SALV group. The groups had similar 5-year overall survival (26% versus 27%). The causes of death in the SALV and NCRS groups were primary esophageal cancer in 35% and 55% of patients, respectively, and pulmonary-related mortality in 24% and 5%, respectively. Multivariable Cox regression analysis revealed the following significant poor prognostic factors: stable disease as the clinical response, preoperative body mass index (BMI) of < 18.5 kg/m, ypN stage 1-3, and R1-2 resection.
SALV was associated with a higher incidence of late pulmonary-related mortality but had a stronger antitumor effect than NCRS. Consequently, the survival rate was similar between the groups. Surgery is recommended for patients with a partial response and preoperative BMI of ≥ 18.5 kg/m.
我们比较了根治性放化疗后计划挽救性手术(SALV)与新辅助放化疗加手术(NCRS)治疗边界可切除 T4 食管鳞癌的效果。
共有 37 例患者接受了计划 SALV,20 例患者接受了 2004 年至 2017 年的 NCRS。短期观察指标为 R0 切除率、并发症和治疗相关死亡率。长期观察指标为 5 年总生存率和死亡原因。
SALV 和 NCRS 两组的 R0 切除率相似(81%与 85%)。SALV 组术后肺炎(35%与 18%)和治疗相关死亡率(9%与 0%)发生率较高。ypT 分级 2-3 级(65%与 30%,p=0.012)和 Clavien-Dindo 分级≥ IIIb 并发症(32%与 0%,p=0.008)在 SALV 组更为常见。两组的 5 年总生存率相似(26%与 27%)。SALV 和 NCRS 组的死亡原因分别为原发性食管癌 35%和 55%,肺部相关死亡率分别为 24%和 5%。多变量 Cox 回归分析显示以下预后不良的因素:疾病稳定作为临床反应、术前 BMI<18.5kg/m、ypN 分期 1-3 期和 R1-2 切除。
SALV 与较高的迟发性肺部相关死亡率相关,但与 NCRS 相比具有更强的抗肿瘤作用。因此,两组的生存率相似。对于部分缓解和术前 BMI≥18.5kg/m 的患者,建议手术治疗。